180
Participants
Start Date
October 24, 2023
Primary Completion Date
January 30, 2026
Study Completion Date
January 30, 2026
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
Treatment B: Budesonide and Formoterol Fumarate
Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
Treatment C : Placebo
Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
WITHDRAWN
Research Site, CABA
RECRUITING
Research Site, Berlin
RECRUITING
Research Site, Berlin
NOT_YET_RECRUITING
Research Site, Santiago de Compostela
RECRUITING
Research Site, Großhansdorf
RECRUITING
Research Site, Lübeck
RECRUITING
Research Site, Madrid
RECRUITING
Research Site, Spartanburg
RECRUITING
Research Site, Greenville
RECRUITING
Research Site, Anderson
RECRUITING
Research Site, Benalmádena
RECRUITING
Research Site, Hanover
RECRUITING
Research Site, Brooksville
NOT_YET_RECRUITING
Research Site, Seville
RECRUITING
Research Site, Daegu
RECRUITING
Research Site, Mainz
RECRUITING
Research Site, Frankfurt
RECRUITING
Research Site, Heidelberg
NOT_YET_RECRUITING
Research Site, Los Angeles
RECRUITING
Research Site, Torrance
NOT_YET_RECRUITING
Research Site, Tarzana
RECRUITING
Research Site, Shenyang
RECRUITING
Research Site, Nanchang
RECRUITING
Research Site, Zhengzhou
RECRUITING
Research Site, Guangzhou
WITHDRAWN
Research Site, Ciudad de Buenos Aires
WITHDRAWN
Research Site, Quilmes
RECRUITING
Research Site, Edmonton
RECRUITING
Research Site, Kingston
RECRUITING
Research Site, Sainte-Foy
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
WITHDRAWN
Research Site, Leeds
RECRUITING
Research Site, Leicester
RECRUITING
Research Site, London
RECRUITING
Research Site, London
RECRUITING
Research Site, Manchester
Lead Sponsor
AstraZeneca
INDUSTRY